OmniAb, Inc.
NASDAQ:OABIBiotechnology
+$0.16 today
- Market cap
- $740.97M
- Beta
- 1.15
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.42
Volume 1.22M
Average 0.67M
OABI Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
OmniAb, Inc.NASDAQ: OABI
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $4.92M (cash outflow) rose 947.2% year over year, ahead of the +247.4% change in trailing-twelve-month accounts receivables. Sequentially, it rose 125.8% from the prior quarter.
Context
- Accounts receivables amounted to 1.0% of revenue in FY2025, down 1.4 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +947.2% holds above the trailing-twelve-month pace of +247.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 189K USD
- Year-over-year change
- +130.2%
- 4-year CAGR
- -57.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 189K | +130.2% |
| FY2024 | 2024-12-31 | (625K) | -102.3% |
| FY2023 | 2023-12-31 | 26.9M | +311.2% |
| FY2022 | 2022-12-31 | (12.74M) | -311.6% |
| FY2021 | 2021-12-31 | 6.02M | — |
Accounts Receivables vs competitors
How OABI compares with its peers on the latest reported figures
- OABI's LTM Mar 2026 accounts receivables of $4.26M is the largest of the 4 companies compared; the peer median is $1.08M.
- Its year-over-year change of +247.4% is the highest of 4, against a peer median of +103.5%.
- Accounts receivables amounts to 14.7% of revenue for OABI, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.26M | +247.4% | — | 14.7% | |
| LTM Mar 2026 | $1.38M | +207.1% | — | 75.4% | |
| LTM Mar 2026 | $1.08M | -93.9% | -4.6% | 1.1% | |
| LTM Mar 2026 | $117K | +103.5% | -41.7% | 0.1% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding OABI) | $1.08M | +103.5% | -23.2% | 1.1% | |
Competitors are the stored peer set for OABI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.04M) | (22.33M) | (50.62M) | (62.03M) | (64.78M) |
| Depreciation & Amortization | 16.25M | 18.25M | 19.5M | 23.58M | 21.75M |
| Deferred Income Tax | (7.33M) | (6.42M) | (12.54M) | (9.04M) | (1.53M) |
| Stock-Based Compensation | 15.07M | 18.32M | 24.82M | 21.5M | 15.82M |
| Change in Working Capital | (2.63M) | (10.83M) | 24.87M | (10.17M) | (4.95M) |
| Accounts Receivables | 6.02M | (12.74M) | 26.9M | (625K) | 189K |
| Inventory | (1.51M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.51M | 15.07M | 920K | (2.41M) | (231K) |
| Other Working Capital | (8.65M) | (13.16M) | (2.95M) | (7.14M) | (4.91M) |
| Other Non-Cash Items | 9K | (572K) | (3.68M) | (3.5M) | (4.3M) |
| Operating Cash Flow | (5.67M) | (3.59M) | 2.35M | (39.66M) | (36.46M) |
| Capital Expenditures | (4.07M) | (17.17M) | (1.64M) | (1.88M) | (565K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (54.78M) | (112.62M) | (40.29M) | (46.86M) |
| Sales of Investments | 1.27M | 70K | 100.32M | 80.45M | 50.89M |
| Other Investing Activities | (1.22M) | (1.44M) | (4.44M) | (400K) | 3M |
| Investing Cash Flow | (4.03M) | (73.31M) | (18.38M) | 37.88M | 6.47M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 96.24M | 0 | 11.37M | 28.36M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.7M | 14.5M | (892K) | 1.65M | (450K) |
| Financing Cash Flow | 9.7M | 110.74M | (892K) | 13.02M | 27.91M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 33.84M | (16.92M) | 11.24M | (2.07M) |
| Free Cash Flow | (9.74M) | (20.76M) | 703K | (41.54M) | (37.02M) |
OmniAb, Inc.
NASDAQ:OABI
Intrinsic Alpha fair value
Locked
Current Price
$5.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.